Medication info
Yudapa Duo Sustained Release Tablet 10/1000 mg

Yudapa Duo Sustained Release Tablet 10/1000 mg

Prescription medicationTabletOral
Ingredient · strength
Metformin Hydrochloride›1000mg / 1 tabletDapagliflozin Propanediol Hydrate›12.3mg / 1 tablet
Manufacturer / importer
YouYoung Pharmaceutical Co., Ltd.
Appearance
Yellow, oval-shaped, bilayered sustained release film-coated tablet
Packaging
30 tablets/bottle
Approval status
Active

MFDS item code 202300191 · Approved 2023.01.10 · Insurance code 648204660

Summary

Main use
Improvement of glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or the nearest appropriate therapeutic dose. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustments made as appropriate. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustments made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to be decreased in elderly patients, this medicine should be used with caution as age increases (see the patient section under '9. Administration to elderly patients' in Precautions for use).

Ingredients

Manufacturer
YouYoung Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in adults with type 2 diabetes mellitus

  • Type 2 diabetes
  • abnormal blood sugar control
  • cardiovascular disease
  • cardiovascular risk factors
View approved original text

This medication is used as a treatment for adult patients with type 2 diabetes who are also following a dietary and exercise regimen, combining dapagliflozin and metformin to help control blood sugar levels. It is important to consult a specialist regarding cardiovascular effects if the patient has cardiovascular disease or risk factors and blood sugar is not adequately controlled. This medication effectively improves blood sugar levels and aids in diabetes management.

How to take

Adult dose

The dose of this medicine should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This medicine is generally administered once daily with the evening meal. The maximum dose of this medicine is dapagliflozin 10mg/extended-release metformin 2000mg once daily, given as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and whose blood glucose is not adequately controlled with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this medicine is one 5mg/500mg or 10mg/500mg tablet once daily. Titrate the dose gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this medicine should provide the patient's current metformin dose or the nearest appropriate therapeutic dose. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustments made as appropriate. In patients switching from combination therapy with dapagliflozin and metformin to this medicine, treatment may be initiated at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and dose adjustments made as appropriate. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. This medicine must be swallowed whole and must never be crushed, cut, or chewed. Renal impairment No dose adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or higher and less than 60 mL/min/1.73 m2, who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, a component of this medicine, is 500mg once daily, and the maximum daily dose is 1000mg. Administration of this medicine is not recommended in patients with an eGFR less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, discontinue this medicine immediately. Renal function should be assessed every 3~6 months. Elderly patients Because metformin is excreted by the kidneys and renal function is more likely to be decreased in elderly patients, this medicine should be used with caution as age increases (see the patient section under '9. Administration to elderly patients' in Precautions for use).

Precautions

This medication is helpful in controlling blood sugar. However, this medication can rarely cause a dangerous condition known as lactic acidosis, so caution is necessary. When taken with other diabetes medications, hypoglycemia may occur, so monitoring blood sugar changes is essential. Patients with poor kidney function, dehydration, severe infections, or heart issues should not take this medication. Additionally, pregnant or breastfeeding women and patients with genetic lactose intolerance should avoid it. Patients with reduced fluid volume or kidney function issues should have their condition carefully assessed before administration, and blood pressure and kidney function should be regularly monitored during usage. While taking this medication, genital infections or urinary tract infections may occur, so prompt treatment is necessary when symptoms arise. Also, hypoglycemic symptoms may appear; hence dose adjustments may be necessary when taken alongside insulin or blood sugar-lowering agents. Long-term use may lead to vitamin B12 deficiency, so regular monitoring of vitamin levels is advisable. Alcohol intake may increase the risk of side effects, so care should be taken to avoid excessive drinking. If undergoing surgery or radiological contrast tests, this medication should be discontinued for a period and restarted only after confirming normal kidney function. In the elderly, decreased kidney function is common, so dosage should be carefully adjusted and kidney function monitored regularly. In case of overdose, immediate consultation with healthcare personnel for appropriate treatment is needed, and although this medication has a minimal effect on driving or operating machinery, caution is necessary due to the potential for dizziness. Keep the medication out of reach of children and store it in its original container to maintain quality.

Side effects

  • Severe lactic acidosis
  • severe hypoglycemia
  • vulvitis
  • balanitis
  • genital infection
  • urinary tract infection
  • fungal infection
  • hypoglycemia
  • decreased fluid volume
  • thirst
Show 85 more
  • diabetic ketoacidosis
  • dizziness
  • constipation
  • dry mouth
  • low back pain
  • dysuria
  • polyuria
  • nocturia
  • vulvar itching
  • genital itching
  • elevated hematocrit
  • decreased renal creatinine clearance
  • dyslipidemia
  • elevated serum creatinine
  • elevated blood urea
  • weight loss
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • acute kidney injury
  • renal dysfunction
  • rash
  • diarrhea
  • nausea
  • vomiting
  • decreased vitamin B12
  • Guillain-Barré syndrome
  • bacterial pneumonia
  • sialadenitis
  • tendinitis
  • chest pain
  • thermal burn
  • wrist fracture
  • gastrointestinal stromal tumor
  • lung malignancy
  • uterine fibroid
  • atrial fibrillation
  • acute cholecystitis
  • upper abdominal pain
  • dyspepsia
  • abdominal discomfort
  • abdominal pain
  • gastric ulcer
  • irritable bowel syndrome
  • salivary gland mass
  • toothache
  • headache
  • facial paralysis
  • peripheral neuropathy
  • sensory disturbances
  • drowsiness
  • tremor
  • nasopharyngitis
  • pharyngitis
  • adenoviral conjunctivitis
  • shingles
  • pneumonia
  • rhinitis
  • elevated alanine aminotransferase
  • increased blood glucose
  • arthralgia
  • myalgia
  • myofascial pain syndrome
  • osteoarthritis
  • osteochondrosis
  • limb pain
  • periartritis
  • tendinopathy
  • trigger finger
  • asthenia
  • fatigue
  • peripheral edema
  • edema
  • pain
  • vitamin D deficiency
  • hyperglycemia
  • urethral syndrome
  • cough
  • hyperventilation
  • skin abrasion
  • pruritus
  • palpitations
  • insomnia
  • Type 2a hyperlipidemia
  • neurogenic hearing loss

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be kept in a tightly closed container to avoid exposure to air or moisture. It is also preferable to store it at room temperature between 1 to 30 degrees Celsius, away from excessively hot or cold environments.

Appearance and packaging

Appearance

Yellow, oval-shaped, bilayered sustained release film-coated tablet

Package unit

30 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.